

# Carbidopa/Levodopa Extended-Release Capsules (CREXONT and RYTARY)

## Criteria for Use

### January 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

### Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive carbidopa/levodopa extended-release capsules.

Currently taking a nonselective monoamine oxidase (MAO) inhibitor (e.g., phenelzine and tranylcypromine) or have recently (within 14 days) taken a nonselective MAO inhibitor

### Inclusion Criteria

All of the following criteria must be met.

- Patient is under the care of a VA or VA Community Care neurologist or locally designated expert
- Clinical diagnosis of Parkinson's disease (PD), post-encephalitic parkinsonism, or parkinsonism that may follow intoxication by carbon monoxide or manganese
- Motor fluctuations ("wearing off") that require dosing of dopaminergic medications at intervals of every 4 hours or less
- Combination of carbidopa/levodopa controlled-release (CR) and immediate-release (IR) tablet formulations throughout the day have not adequately resolved OFF periods
- Contraindication, intolerance, or inadequate therapeutic response to at least one agent from two of the following classes: dopamine agonist, catechol-O methyl transferase [COMT] inhibitor, monoamine oxidase type B [MAO B] inhibitor

### Supplemental Information

- Refer to product's prescribing information to determine the recommended dosing based on the patient's current carbidopa/levodopa dose and other PD therapies (e.g., COMT inhibitors).

---

Prepared: October 2015. Revised: January 2025. Contact: N. Antonovich, PharmD, BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)

---